Atezolizumab, Cobimetinib, and Eribulin in Treating Patients With Chemotherapy Resistant Metastatic Inflammatory Breast Cancer

PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 11, 2017

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions

Recurrent Breast Inflammatory CarcinomaStage IV Breast Inflammatory Carcinoma

Interventions

DRUG

Atezolizumab

Given IV

DRUG

Cobimetinib

Given PO

DRUG

Eribulin

Given IV

OTHER

Laboratory Biomarker Analysis

Correlative studies

OTHER

Pharmacological Study

Correlative studies

Trial Locations (1)

M D Anderson Cancer Center, Houston

All Listed Sponsors

lead

M.D. Anderson Cancer Center

OTHER